Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003641 | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | completed | Phase 3 | 1,150 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Sep 29, 2026 | clinicaltrials |
| NCT01720407 | Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face(ImiReduc) | completed | Phase 3 | 259 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 |
| clinicaltrials |
| NCT02678572 | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma(FOCUS) | completed | Phase 3 | 102 | Delcath Systems Inc.INDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT02997553 | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery(GASVERT) | completed | Phase 3 | 744 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06320353 | Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | completed | Phase 3 | 266 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01989572 | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery | completed | Phase 3 | 815 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).(COMBI-AD) | completed | Phase 3 | 870 | Novartis PharmaceuticalsINDUSTRY | 25 | Apr 21, 2026 | clinicaltrials |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | completed | Phase 3 | 256 | AmgenINDUSTRY | 22 | Mar 27, 2026 | clinicaltrials |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma(COLUMBUS) | completed | Phase 3 | 921 | PfizerINDUSTRY | 29 | Feb 27, 2026 | clinicaltrials |
| NCT03820986 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) | completed | Phase 3 | 674 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Feb 9, 2026 | clinicaltrials |
| NCT01983748 | Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma | completed | Phase 3 | 200 | University Hospital ErlangenOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04889118 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study | completed | Phase 3 | 131 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02752074 | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) | completed | Phase 3 | 706 | Incyte CorporationINDUSTRY | 23 | Aug 24, 2025 | clinicaltrials |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | completed | Phase 3 | 945 | Bristol-Myers SquibbINDUSTRY | 22 | May 21, 2025 | clinicaltrials |
| NCT02166788 | Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma(EAGLE FM) | completed | Phase 3 | 634 | Melanoma and Skin Cancer Trials LimitedOTHER | 6 | May 9, 2025 | clinicaltrials |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT02388906 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma(CheckMate 238) | completed | Phase 3 | 906 | Bristol-Myers SquibbINDUSTRY | 25 | Apr 24, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT03172299 | Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma(PROTECT) | completed | Phase 3 | 57 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT02278887 | Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma(TIL) | completed | Phase 3 | 168 | The Netherlands Cancer InstituteOTHER | 2 | Mar 10, 2025 | clinicaltrials |
| NCT05297565 | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection(CheckMate-6GE) | completed | Phase 3 | 14 | Bristol-Myers SquibbINDUSTRY | 7 | Feb 27, 2025 | clinicaltrials |
| NCT02993315 | Melanoma Patients Immunized with Natural DenDritic Cells(MIND-DC) | completed | Phase 3 | 148 | Radboud University Medical CenterOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03430297 | A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma(JS001) | completed | Phase 3 | 256 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02394132 | Radiotherapy or Imiquimod in Complex Lentigo Maligna(RADICAL) | completed | Phase 3 | 126 | Melanoma and Skin Cancer Trials LimitedOTHER | 3 | Jun 20, 2024 | clinicaltrials |
| NCT01785316 | The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases(SCANDIUM) | completed | Phase 3 | 93 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT00003027 | Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma | completed | Phase 3 | 482 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003444 | Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin | completed | Phase 3 | 167 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01359956 | Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma(SICOG 0109) | completed | Phase 3 | 269 | National Cancer Institute, NaplesOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT03294330 | SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer(SPYX) | completed | Phase 3 | 35 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02843386 | Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma(FOTEADJ) | completed | Phase 3 | 302 | Institut CurieOTHER | 2 | Aug 31, 2022 | clinicaltrials |
| NCT01721772 | Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma(CheckMate 066) | completed | Phase 3 | 418 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 12, 2022 | clinicaltrials |
| NCT02714218 | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | completed | Phase 3 | 387 | Bristol-Myers SquibbINDUSTRY | 13 | Jun 24, 2022 | clinicaltrials |
| NCT01689519 | A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma(coBRIM) | completed | Phase 3 | 495 | Hoffmann-La RocheINDUSTRY | 19 | May 2, 2022 | clinicaltrials |
| NCT01721746 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | completed | Phase 3 | 405 | Bristol-Myers SquibbINDUSTRY | 14 | Apr 19, 2022 | clinicaltrials |
| NCT03068455 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma(CheckMate 915) | completed | Phase 3 | 1,844 | Bristol-Myers SquibbINDUSTRY | 19 | Sep 20, 2021 | clinicaltrials |
| NCT03329846 | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | completed | Phase 3 | 20 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 9, 2021 | clinicaltrials |
| NCT00324727 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | completed | Phase 3 | 93 | Delcath Systems Inc.INDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02599402 | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma(CheckMate 401) | completed | Phase 3 | 533 | Bristol-Myers SquibbINDUSTRY | 12 | Jun 15, 2021 | clinicaltrials |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma(COMBI-v) | completed | Phase 3 | 704 | Novartis PharmaceuticalsINDUSTRY | 28 | Feb 24, 2021 | clinicaltrials |
| NCT01584648 | A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma | completed | Phase 3 | 423 | Novartis PharmaceuticalsINDUSTRY | 14 | Feb 17, 2021 | clinicaltrials |
| NCT02905266 | A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | completed | Phase 3 | 106 | Bristol-Myers SquibbINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01866319 | Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | completed | Phase 3 | 834 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 2, 2020 | clinicaltrials |
| NCT02545075 | A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine | completed | Phase 3 | 182 | Bristol-Myers SquibbINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT00057616 | Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. | completed | Phase 3 | 274 | CelgeneINDUSTRY | 9 | Nov 8, 2019 | clinicaltrials |
| NCT00864253 | A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma | completed | Phase 3 | 529 | CelgeneINDUSTRY | 9 | Oct 30, 2019 | clinicaltrials |
| NCT01515189 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | completed | Phase 3 | 831 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 31, 2019 | clinicaltrials |
| NCT01667419 | A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma(BRIM8) | completed | Phase 3 | 498 | Hoffmann-La RocheINDUSTRY | 29 | Jul 23, 2019 | clinicaltrials |
| NCT01245062 | GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | completed | Phase 3 | 322 | GlaxoSmithKlineINDUSTRY | 19 | Apr 5, 2018 | clinicaltrials |
Data updated 10 hours agoSource updated Sep 29, 2026source: clinicaltrials